Steward Partners Investment Advisory’s MoonLake Immunotherapeutics MLTX Stock Holding History

Steward Partners Investment Advisory’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.69K	Buy	395 +151	+62%	+$2.74K	﹤0.01%	3830
2026 Q1	$4.55K	Buy	244 +149	+157%	+$2.47K	﹤0.01%	3828
2025 Q4	$1.25K	Hold	95	–	–	﹤0.01%	4052
2025 Q3	$681	Buy	+95	New	+$4.95K	﹤0.01%	4089
2023 Q4	–	Sell	-200	Closed	-$11.4K	–	3534
2023 Q3	$11.4K	Buy	+200	New	+$11K	﹤0.01%	2546

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steward Partners Investment Advisory's MLTX Position: Q2 2026 in Review

Steward Partners Investment Advisory increased its MoonLake Immunotherapeutics (MLTX) stake by 62% in Q2 2026, buying an estimated $2.74K and bringing the position to 395 shares worth $7.69K. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

Steward Partners Investment Advisory first reported a position in MLTX in Q3 2023 and has held it in 5 quarters since. The position peaked at $11.4K in Q3 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Steward Partners Investment Advisory held 395 shares of MoonLake Immunotherapeutics worth $7.69K as of Q2 2026.
Steward Partners Investment Advisory bought 151 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $2.74K.
MoonLake Immunotherapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #3830 holding.
Steward Partners Investment Advisory first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 5 quarters since.
Steward Partners Investment Advisory's MoonLake Immunotherapeutics position peaked at $11.4K in Q3 2023.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.